MATURA - Highlights and News

MAximising Therapeutic Utility in Rheumatoid Arthritis

Highlights and News

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers: Clinical implications of synovial tissue phenotypes in rheumatoid arthritis Frontiers
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature.com: Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue Nature.com
Rheumatoid arthritis - The Lancet: Rheumatoid arthritis The Lancet
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK - The BMJ: Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK The BMJ
Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of Translational Medicine: Are innovation and new technologies in precision medicine paving a new era in patients centric care? Journal of Translational Medicine
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers: Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers: A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients Frontiers

The MATURA consortium includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis

Highlights and News

Related